清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Incidence, outcomes, and risk factors of acute immune checkpoint inhibitor (ICI) pneumonitis post-chemoradiation with durvalumab for patients with locally advanced non-small cell lung cancer (LA-NSCLC): A population-based multicenter study.

杜瓦卢马布 医学 肺炎 内科学 肺癌 放射治疗 肿瘤科 癌症 肺 彭布罗利珠单抗 免疫疗法
作者
Chloe Lim,Sunita Ghosh,Hali Morrison,Daniel E. Meyers,Igor Stukalin,Samantha Dolter,Heidi A.I. Grosjean,Marc Kerba,Desirée Hao,Aliyah Pabani
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 8561-8561
标识
DOI:10.1200/jco.2023.41.16_suppl.8561
摘要

8561 Background: The PACIFIC trial has drastically changed the LA-NSCLC treatment paradigm and improved survival outcomes with consolidation durvalumab post-chemoradiotherapy. Despite these promising results, real-world practice has demonstrated that ICI pneumonitis can have significant clinical complications and terminate consolidation therapy prematurely. This study aimed to identify clinical predictors, outcomes, and healthcare utilization in ICI pneumonitis in LA-NSCLC patients who received consolidation durvalumab in real-world practice. Methods: Using the Alberta Immunotherapy Database, we retrospectively evaluated all NSCLC patients who received durvalumab in Alberta, Canada from January 2018 to December 2021. Pneumonitis cases were identified based on radiographic changes and oncologists’ clinical assessments. We examined incidence and predictive values of severe pneumonitis (≥grade 3), with secondary outcomes of overall survival (OS) and time-to-treatment failure (TTF). Exploratory multivariate analyses were performed to identify predictive values to developing severe pneumonitis and worse OS/TTF. Results: Of 189 total patients, most were ECOG 0-1 (91%) and had partial response from chemoradiation (85%) prior to durvalumab. 49% received full year of therapy (n = 93). Median TTF was 11.2 months, and median OS of 19.7 months with 1-year OS 64% (n = 121). 26% (n = 49) developed any grade of pneumonitis. 9% (n = 17) had severe pneumonitis. Corticosteroids were administered to 86% of the pneumonitis patients (n = 42); 53% (n = 26) required admission. 13% (n = 9) of deaths were attributed to pneumonitis. Male gender and pre-existing autoimmune condition were associated with severe pneumonitis whereas V 20 (percentage of irradiated lung volume ≥20Gy) was associated with developing any grade pneumonitis. In multivariable analysis, male gender and V 20 was significantly associated with worse OS whereas older age, smoking status, pneumonitis, and male gender with lower TTF. Pneumonitis development was found to be an independent risk factor for worse OS (p = 0.038) and TTF (p = 0.007). Conclusions: We report a pneumonitis incidence comparable to prior retrospective studies and higher rate of severe pneumonitis compared to PACIFIC trial. Our results corroborate that V 20 , a previously established risk factor for durvalumab associated pneumonitis, is a significant predictor for developing pneumonitis and worse OS. In contrast to smaller retrospective studies, we observed male gender and pre-existing autoimmune conditions appear to predict severe durvalumab associated ICI pneumonitis. These results affirm the importance of careful patient selection for safe completion of consolidation durvalumab in real-world LA-NSCLC population.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
笑点低小霜完成签到,获得积分10
刚刚
刻苦的刚完成签到,获得积分10
7秒前
8秒前
重要盼易完成签到,获得积分10
11秒前
Tracy发布了新的文献求助10
13秒前
典雅的醉易完成签到,获得积分10
36秒前
冷酷紫烟完成签到,获得积分10
38秒前
深情的晓槐完成签到,获得积分10
46秒前
Aman完成签到,获得积分10
50秒前
可靠秋蝶完成签到,获得积分10
57秒前
超帅黑夜完成签到,获得积分10
1分钟前
CodeCraft的应助被无限幻枫采纳,获得10
1分钟前
火星上安柏完成签到,获得积分10
1分钟前
1分钟前
贪玩的夏真完成签到,获得积分10
1分钟前
科研通AI6.4的应助被xingsixs采纳,获得10
1分钟前
风中的世平完成签到,获得积分10
1分钟前
Aman完成签到,获得积分10
1分钟前
懒得起名字完成签到 ,获得积分10
1分钟前
温暖的胜完成签到,获得积分10
1分钟前
无悔完成签到 ,获得积分0
1分钟前
纯真的雁凡完成签到,获得积分10
1分钟前
柔弱的铅笔完成签到,获得积分10
1分钟前
Tracy发布了新的文献求助10
2分钟前
2分钟前
顺利夏云完成签到,获得积分10
2分钟前
xingsixs发布了新的文献求助10
2分钟前
Tracy完成签到,获得积分10
2分钟前
zwlei完成签到,获得积分10
2分钟前
腼腆的雪珊完成签到,获得积分10
2分钟前
热情的衬衫完成签到,获得积分10
2分钟前
xingsixs完成签到,获得积分10
2分钟前
危机的白凡完成签到,获得积分10
2分钟前
徐伟业完成签到 ,获得积分10
3分钟前
RetchieLi完成签到,获得积分10
3分钟前
3分钟前
无限幻枫发布了新的文献求助10
3分钟前
眼睛大的向彤完成签到,获得积分10
3分钟前
俭朴映寒完成签到,获得积分10
3分钟前
汉堡包的应助被bluemoon采纳,获得10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158937
求助须知:如何正确求助?哪些是违规求助? 9554526
关于积分的说明 21719385
捐赠科研通 7748487
什么是DOI,文献DOI怎么找? 3427107
关于科研通互助平台的介绍 2552013
邀请新用户注册赠送积分活动 2471370